The significant fall in both the share price and revenue of ...
The significant fall in both the share price and revenue of Blueprint Medicines Corporation could indicate unresolved issues within the company. The continued lack of profitability may also be a concern for long-term investors.
Loss-making Blueprint Medicines (NASDAQ:BPMC) Sheds a Further US$118m, Taking Total Shareholder Losses to 53% Over 3 Years
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment